Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and the development path he will follow in order to foster growth.
You took over the helm of the Mexican affiliate of Eisai in January 2016, a strategic market for the group, alongside Russia, Brazil, Canada, and Australia. What were your first impressions on joining the company?
Although many pharma companies have now put patient-centricity at the core of their marketing strategy, this hhc philosophy stands out as Eisai’s driver on a daily basis
